Whether private or public, early or late stage, management teams and shareholders are turning to debt more often to lower their cost of capital and extend cash runways. Panel members representing equipment and growth lending, royalty financing, receivables financing and venture capital will offer perspectives and recommendations on appropriate senior debt products, market terms and optimal procurement timing.

Objective1:Provide information on the array of senior debt products available to life science companies.

Objective2:Help CEOs and CFOs of early- to late-stage private and public companies make decisions on the optimal mix, terms and timing of senior debt products.

Objective3:Share debt procurement experiences of seasoned life science company financial executives.